Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The breast cancer resistance protein ABCG2 is implicated in multidrug resistance.
• Understanding ABCG2 regulation is crucial for improving cancer chemotherapy.
• Hormonal influences on ABCG2 expression are not fully elucidated.

Purpose of the Study:

• To investigate the effect of dexamethasone (DEX) and progesterone (PROG) on ABCG2 expression in breast cancer cells.
• To explore the role of progesterone receptor (PR), Pregnane X Receptor (PXR), and Glucocorticoid Receptor (GR) signaling pathways in ABCG2 regulation.

Main Methods:

• Utilized MCF7 (PR-positive) and MDA-MB-231 (PR-negative) breast cancer cell lines.
• Created stable transfectants of MDA-MB-231 cells expressing PR isoforms A and B.
• Administered DEX, PROG, and other PXR/GR ligands to cells.
• Assessed ABCG2 expression levels.
• Evaluated cellular sensitivity to mitoxantrone.

Main Results:

• DEX and PROG strongly inhibited ABCG2 expression in PR-positive MCF7 cells.
• DEX and PROG strongly up-regulated ABCG2 expression in PR-negative MDA-MB-231 cells engineered to express PR.
• Other PXR/GR ligands also down-regulated ABCG2 in MCF7 cells.
• DEX-mediated inhibition of ABCG2 correlated with increased sensitivity to mitoxantrone.

Conclusions:

• DEX and PROG differentially regulate ABCG2 expression based on PR status.
• PR, PXR, and GR signaling pathways are involved in controlling ABCG2 expression.
• DEX shows potential for enhancing chemotherapy efficacy by inhibiting ABCG2.